Breast cancer and immunology: biomarker and therapeutic developments

References

• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Curigliano G. Immunotherapeutics for breast cancer. Curr Opin Oncol 2013;25(6):602-8
   PubMed Web of Science ®Google Scholar
• Milani A, Sangiolo D, Aglietta M, Valabrega G. Recent advances in the development of breast cancer vaccines. Breast cancer (Dove Medical Press) 2014;6:159-68
   PubMedGoogle Scholar
• Jager E, Ringhoffer M, Karbach J, et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Inter J Can 1996;66(4):470-6
   PubMed Web of Science ®Google Scholar
• Cunningham TJ, Olson KB, Laffin R, et al. Treatment of advanced cancer with active immunization. Cancer 1969;24(5):932-7
   PubMed Web of Science ®Google Scholar
• Menard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997;3(5):817-19
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Gomez S, Arenas A, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 2010;10:604
   PubMed Web of Science ®Google Scholar
• An T, Sood U, Pietruk T, et al. In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol 1987;128(1):52-60
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2014;26(2):259-71
   PubMed Web of Science ®Google Scholar
• Melichar B, Studentova H, Kalabova H, et al. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res 2014;34(3):1115-25
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28(1):105-13
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31(7):860-7
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Annals of oncology 2014;25(8):1544-50
   PubMed Web of Science ®Google Scholar
• Perez EA, Ballman KV, Anderson SK, et al. Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. San Antonio Breast Cancer Symposium; San Antonio, TX, 2014
   Google Scholar
• Dieci MV, Bisagni G, Cagossi K, et al. Tumor infiltrating lymphocytes and correlation with outcomes in the Cher-LOB study. San Antonio Breast Cancer Symposium, San Antonio, TX, 2014
   Google Scholar
• Ernst B, Anderson KS. Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 2015;17(2):426
   Google Scholar
• Vassilaros S, Tsibanis A, Tsikkinis A, et al. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013;5(11):1177-82
   PubMed Web of Science ®Google Scholar
• Miles DW, Towlson KE, Graham R, et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996;74(8):1292-6
   PubMed Web of Science ®Google Scholar
• Miles D, Roche H, Martin M, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 2011;16(8):1092-100
   PubMed Web of Science ®Google Scholar
• Chen G, Gupta R, Petrik S, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res 2014;2(10):949-61
   PubMed Web of Science ®Google Scholar
• Cyclophosphamide and vaccine therapy with or without trastuzumab in treating patients with metastatic breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00971737
   Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Annals of oncology 2014;25(9):1735-42
   PubMed Web of Science ®Google Scholar
• Efficacy and safety study of neuvax™ (nelipepimut-S or E75) vaccine to prevent breast cancer recurrence (PRESENT). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01479244
   Google Scholar
• Vaccine therapy with or without polysaccharide-K in treating patients with stage IV HER2 positive breast cancer receiving HER2-targeted monoclonal antibody therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01922921
   Google Scholar
• Phase Ib trial of two folate binding protein peptide vaccines (E39 and J65) in breast and ovarian cancer patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02019524
   Google Scholar
• Ogi C, Aruga A. Approaches to improve development methods for therapeutic cancer vaccines. Immun letters 2015;164(2):100-8
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Mohammed S, Al-Omair A, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (New York, NY) 2006;8(3):190-8
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2(4):361-70
   PubMed Web of Science ®Google Scholar
• Muenst S, Soysal SD, Gao F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013;139(3):667-76
   PubMed Web of Science ®Google Scholar
• Wimberly H, Brown JR, Schalper KA, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 2014;3(4):326-32
   Google Scholar
• Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014;20(10):2773-82
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-44
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372(26):2521-32
   PubMed Web of Science ®Google Scholar
• Pembrolizumab shows potential in breast cancer. Cancer discovery 2015;5(2):100-1
   Google Scholar
• Emens LA, Braiteh F, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium, San Antonio, TX, 2014
   Google Scholar
• Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA). Available from: https://clinicaltrials.gov/ct2/show/NCT02129556
   Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28(19):3167-75
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515(7528):563-7
   PubMed Web of Science ®Google Scholar
• Callahan MK. Understanding the biology behind responses to immunotherapy. ASCO Annual Meeting, Chicago, IL, 2014
   Google Scholar
• Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park, NY) 2014;28:11 Suppl 3
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568-71
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3(7):611-18
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11(2 Pt 1):728-34
   PubMed Web of Science ®Google Scholar
• Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998;95(17):10067-71
   PubMed Web of Science ®Google Scholar
• Wang Q, Li SH, Wang H, et al. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res 2012;72(17):4417-28
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010;16(13):3485-94
   PubMed Web of Science ®Google Scholar
• Page D, Yuan J, Diab A, et al. editors. Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts). San Antonio Breast Cancer Symposium, San Antonio, TX, 2014
   Google Scholar
• Yuan J, Zhou J, Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014;2(2):127-32
   PubMed Web of Science ®Google Scholar
• Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116(7):1767-75
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015;160(1-2):48-61
   PubMed Web of Science ®Google Scholar
• Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immun 2012;61(7):1019-31
   Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Eng J Med 2014;371(23):2189-99
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107(9):4275-80
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10(11):1185-92
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372(21):2006-17
   PubMed Web of Science ®Google Scholar
• Antonio S, Goldberg S, Balmanoukian A, et al. A Phase 1 open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC). Annual ESMO Meeting. 2014
   Google Scholar
• Morris A, Vetto JT, Ramstad T, et al. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat 2001;67(1):71-80
   PubMed Web of Science ®Google Scholar
• Ramstad T, Lawnicki L, Vetto J, Weinberg A. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg 2000;179(5):400-6
   PubMed Web of Science ®Google Scholar
• Ali SA, Ahmad M, Lynam J, et al. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine 2004;22(27-28):3585-94
   PubMed Web of Science ®Google Scholar
• Guo Z, Wang X, Cheng D, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014;9(2):e89350
   PubMed Web of Science ®Google Scholar
• A Phase 1b/2 safety and tolerability of MEDI6469 in combination with therapeutic immune agents or monoclonal antibodies. Available from: https://clinicaltrials.gov/ct2/show/NCT02205333
   Google Scholar
• Soliman HH, Jackson E, Neuger T, et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 2014;5(18):8136-46
   PubMedGoogle Scholar
• Study of chemotherapy in combination with IDO inhibitor in metastatic breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01792050
   Google Scholar
• Anyaegbu CC, Lake RA, Heel K, et al. Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One 2014;9(9):e107894
   Google Scholar
• Lesterhuis WJ, Salmons J, Nowak AK, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 2013;8(4):e61895
   PubMed Web of Science ®Google Scholar
• Safety study of nivolumab with nab-paclitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage IIIB/IV non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02309177
   Google Scholar
• Balko JM, Denkert C, Salgado R, et al. Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival. San Antonio Breast Cancer Symposium. San Antonio, TX, 2014
   Google Scholar
• Wrangle J, Wang W, Koch A, et al. Alterations of immune response of Non-small cell lung cancer with azacytidine. Oncotarget 2013;4(11):2067-79
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123-35
   PubMed Web of Science ®Google Scholar